As AIM turns 30 this week I’ve been reflecting on the 5 IPOs I’ve done on the market since 2012.
European Green Trns. (AIM:EGT) Results for the year ended 31 December 2024
European Green Transition (AIM: EGT), a company which aims to capitalise on the opportunities created by the green energy transition in Europe, announces it audited results for the year ended 31
Poolbeg Pharma PLC (AIM:POLB) FDA Orphan Drug Designation granted for POLB 001
Poolbeg Pharma PLC (AIM: POLB) has received a significant regulatory endorsement from US authorities for one of its experimental treatments, which aims to address a serious side effect of advanced
Poolbeg Pharma PLC (AIM:POLB) Result of upsized oversubscribed BookBuild Offer
Poolbeg Pharma plc (AIM: POLB), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that, further to the announcements made on 20
Poolbeg Pharma plc (AIM:POLB) Increase of BookBuild Offer
Poolbeg Pharma plc (AIM: POLB, ‘Poolbeg Pharma’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that, further to
HVO, POLB, IMM, AVCT & OPTI – 5 Junior Stocks With High-Stakes Potential in 2025
In today’s rapidly evolving healthcare landscape, several innovative companies are making significant strides in addressing some of the world’s most pressing health challenges. From cutting-edge vaccine trials to pioneering treatments
European Green Transition (AIM:EGT) Extension granted for Olserum REE Project
Successful extension granted for Olserum REE Project
HVO, POLB, IMM, AVCT & OPTI – 5 Junior Stocks With High-Stakes Potential in 2025
In today’s rapidly evolving healthcare landscape, several innovative companies are making significant strides in addressing some of the world’s most pressing health challenges. From cutting-edge vaccine trials to pioneering treatments
HVO, POLB, IMM, AVCT & OPTI – 5 Junior Stocks With High-Stakes Potential in 2025
In today’s rapidly evolving healthcare landscape, several innovative companies are making significant strides in addressing some of the world’s most pressing health challenges. From cutting-edge vaccine trials to pioneering treatments
European Green Transition (AIM:EGT) Board Changes
European Green Transition (AIM: EGT), a company developing green economy assets in Europe, is pleased to announce the appointment of Cathal Friel, the Company’s co-founder, as non-executive Chairman with immediate
European Green Transition (AIM:EGT) Successful extension granted for exploration licences
European Green Transition (AIM: EGT), a company developing green economy assets in Europe, is pleased to announce the granting of a three year extension for the Pajala copper-graphite licences (Liviovaara 101
Poolbeg Pharma PLC (AIM:POLB) Conference Participation in March & April 2025
Poolbeg to present at Master Investor Show, BioTrinity & Participate in a Panel Discussion at LSX World Congress